🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Delivered a talk on ‘Landmark Achievements in Choroidal Diseases’ at International Council of Ophthalmology's World Ophthalmology Congressin Barcelona on June 17, at WOC Day of Landmark Achievements III (2016-2018). #ophthalmology #retina #WOC2018

Dr Jay Kumar Chhablani has been invited to join the editorial board of American Journal of Ophthalmology.

Happy Holidays Kenneth Cole

During AMD/Low Vision Awareness Month (February 2021), we congratulate Dr. Jay Kumar Chhablani of the University of Pittsburgh -- Recognized as an Expertscape Expert in Macular Edema. expertscape.com/ex/macular+ede…

so glad to be here at #arvo2022 ....18 presentations....12 abstracts from our "CAR (Choroid Analysis Research) Lab"....Thanks to the amazing team...#Ophthalmology #upmc

Our work on "Volumetric choroidal vessel segmentation" just got published after hard work for 3 years. Kudos to Mohammed Nasar Ibrahim (first author) and Kiran Vupparaboina, who leads our AI work @ChoroidalAnalysis&Research (CAR) Lab.

We're excited to announce SightBot 👁️🤖, a #ChatGPT-powered chatbot you can chat with about biomedical research topics and receive responses with PubMed citations! Built on LangChain. brilliantly.ai/blog/sightbot

Last, but not least, a special thanks to our amazing collaborators: SightBot was made in partnership with Nikita Kedia and jay chhablani of the University of Pittsburgh!

How is the racial distribution in our clinical trials? Our recent study published in Ophthalmology Retina shows "Black, Asian, and Hispanic patients remain significantly underrepresented among the DME clinical trial patient population based on diabetes prevalence."

I am honoured to announce that we have been awarded Thome Foundation grant for our project: "Personalized Assembloid Platform for Drug Discovery and Modelling of Age-Related Macular Degeneration."

An innovative AI-powered tool for segmenting geographic atrophy (GA) and ellipsoid zone (EZ) loss. This tool enables precise AI-driven segmentation while allowing manual correction, ensuring users can validate each scan for EZ loss and hypertransmission with confidence.

I’m happy to share that I’m starting a new position as Vice Chair, Clinical Trials at Pitt Department of Ophthalmology/UPMC Vision Institute!